Board of Directors
Michael T. Cullen, M.D., MBA
Co-Founder, Executive Chairman
Dr. Cullen brings 25 years of pharmaceutical experience to Sun BioPharma, including expertise in working with development-stage companies in planning, designing and advancing drug candidates from preclinical through clinical development. Dr. Cullen developed several oncology drugs as Chief Medical Officer for MGI Pharma Inc. from 2000 to 2008, and previously at G.D. Searle, SunPharm Corporation, and as Vice President for Clinical Consulting at IBAH Inc., the world’s fifth largest contract research organization, where he provided consulting services on business strategy, creating development plans, regulatory matters and designing clinical trials for several development stage companies in the pharmaceutical industry. Dr. Cullen was also a co-founder and Chief Executive Officer of IDD Medical, a pharmaceutical start-up company. Dr. Cullen joined 3M Pharmaceuticals in 1988 and contributed to the development of cardiovascular, pulmonary and immune-response modification drugs. Over the course of his career Dr. Cullen has been instrumental in obtaining the approval of ten drugs, including three (3) since 2004: Aloxi®, Dacogen® and Lusedra®. Board-certified in Internal Medicine, Dr. Cullen practiced from 1977 to 1988 at Owatonna Clinic, Owatonna, MN, where he served as president. Dr. Cullen earned his MD and BS degrees from the University of Minnesota and his MBA from the University of St. Thomas and completed his residency and Board certification in Internal Medicine through the University of North Carolina in Chapel Hill and Wilmington, NC.
David B. Kaysen
President, Chief Executive Officer
Mr. Kaysen brings more than 25 years of executive healthcare clinical and regulatory development, commercial execution and publicly traded company achievements. Prior to joining Sun BioPharma, Inc. Mr. Kaysen was an advisor and senior executive for several domestic and European growth-oriented privately-held healthcare companies. From 2006 until 2013 Mr. Kaysen served as President, Chief Executive Officer and Member of the Board of Directors of Uroplasty, Inc., a Minneapolis based publicly traded global medical device company where he guided the company through successful clinical trials, regulatory approvals, raised four rounds of equity capital and grew annual sales to over $23 million. Previously, Mr. Kaysen served as President and Chief Executive Officer of Advanced Duplication Services, LLC, a privately-held replicator and duplicator of optical media; President, Chief Executive Officer and Member of the Board of Directors of Diametrics Medical, Inc. a publicly traded global manufacturer and marketer of critical care blood analysis systems; and President, Chief Executive Officer and Member of the Board of Directors of Rehabilicare Inc., a publicly traded global manufacturer and marketer of neuromodulation devices for rehabilitation and pain management. Mr. Kaysen currently serves on the Board of Directors of four privately-held companies, three of which are in the health care space. Mr. Kaysen received a Bachelor of Science degree in Business Administration from the University of Minnesota.
Chairman of the Compensation Committee and Member of the Nominating and Corporate Governance Committee
Mr. Schemel has over 39 years’ experience in the agriculture industry. From 1973-2005, Mr. Schemel owned and operated a farming operation in Kandiyohi County, Minnesota, building a 5000-acre operation producing corn, soybeans and sugar beets. Mr. Schemel has extensive experience in serving on Boards of Directors. From 1992-1996 he served as a board member for ValAdCo and then from 1996-2003 he served as the Chairman of the Board for Phenix Biocomposites. He is currently a member of the Southern Minnesota Beet Sugar Co-op which oversees the operation of the largest US sugar processing facility and a molasses desugarization facility in Renville, Minnesota, which has a total economic benefit currently exceeding $180 million annually.
Paul W. Schaffer, PharmD
Member of the Compensation and Audit Committee
Mr. Schaffer was elected to the Board of Directors in January 2014. Mr. Schaffer graduated from University of Minnesota School of Pharmacy in 1966. He owned and operated a compounding pharmacy, Bloomington Drug, for 42 years. Mr. Schaffer has considerable experience in biotech investments, and expertise in the pharmaceutical industry.
J. Robert Paulson, Jr., MBA
Chairman of the Nominating and Corporate Governance Committee and Member of Audit, Compensation Committee
Mr. Paulson is President, CEO, and a Director of NxThera, Inc., a venture-funded medical device company developing a novel convective water vapor energy system to treat a variety of endourological conditions, including benign prostatic hyperplasia (BPH) and prostate cancer. Prior to joining NxThera in 2009, Bob was President, CEO and a Director of Restore Medical from 2005 until the company’s acquisition by Medtronic in July of 2008. Previous to Restore, Bob was CFO and VP of Global Marketing for Endocardial Solutions, which was acquired by St. Jude Medical in 2005. Bob was the Sr. VP/General Manager of Advanced Bionics, and held several executive positions with Medtronic, including VP/General Manager of the Surgical Navigation Technologies business, VP Corporate Strategy, and Director of Corporate Development. Bob held senior positions in marketing, corporate development, legal and finance at General Mills, and practiced corporate, M&A and securities law with the Minneapolis law firm of Lindquist & Vennum. Bob currently serves as a director of Veran Medical, and has been a director of several privately-held and public medical devices companies, including Ablation Frontiers, Vascular Solutions and Medical CV. Bob has been a director of several charitable foundations including director and chair of the Sister Kenny Foundation, Pillsbury Neighborhood Services, and the Washburn Child Guidance Center. Bob is a member of the Luther College Board of Regents and is a member of the executive council and past-president of St. Philip the Deacon Lutheran Church.
Chairman of the Audit Committee, Member of the Nominating and Corporate Governance Committee
Mr. Mathiesen serves as Chief Financial Officer of Gemphire Therapeutics Inc., a publicly traded biopharmaceutical company. Prior to joining Gemphire, Mr. Mathiesen served as Chief Financial Officer of Sunshine Heart, Inc., a publicly traded medical device company, from March 2011 to January 2015. From December 2005 to April 2010, Mr. Mathiesen served as Vice President and Chief Financial Officer of Zareba Systems, Inc., a manufacturer and marketer of medical products, perimeter fencing and security systems, which was purchased by Woodstream Corporation in April 2010. Mr. Mathiesen has held executive positions with publicly traded companies dating back to 1993, including Vice President and Chief Financial Officer positions. He has served as a director of NeuroOne, Inc., a private medical device company, since April 2017. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant.
Suzanne Gagnon, M.D.
Chief Medical Officer
Dr. Gagnon has been leading the medical, regulatory and safety aspects of pharmaceutical product development for more than 20 years, including senior management positions as both an academic researcher and in the Pharmaceutical and CRO industries. She served as Chief Medical Officer at Idis, a company focused on providing global access to medicines to patients with unmet medical needs, and at NuPathe Inc., a biopharmaceutical company focused on innovations in neuroscience, prior to its acquisition by Teva Pharmaceuticals. Between 2001 and 2011 she was Chief Medical Officer and Executive Vice President at ICON Clinical Research, a top tier CRO recognized in 2009 as #49 on the FORTUNE list of “100 Fastest Growing Companies.” She began her industry career at Rhone-Poulenc Rorer, currently Sanofi, where she participated in the development of Taxotere® (docetaxel) for the treatment of breast and lung cancer, and led the regulatory approval process in the U.S. and Canada for Venofer® (iron sucrose) as Vice President of Clinical R&D at Luitpold Pharmaceuticals, a Daiichi Sankyo Company. Dr. Gagnon received her medical degree from Boston University School of Medicine, became Board Certified in Internal Medicine at Boston City Hospital and spent several years on faculty at the University of Miami School of Medicine where she published independently conducted clinical research in the New England Journal of Medicine prior to joining the industry. She is an international editorial advisor to Elsevier Publishing, the author or co-author of numerous publications, abstracts and book chapters and a frequent international speaker. She currently holds a position as adjunct Professor in Pharmaceutical Product Development at West Chester University of Pennsylvania.
Dalvir Gill, Ph.D.
Dalvir Gill, Ph.D., currently serves as the Chief Executive Officer of TransCelerate BioPharma Inc., a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, prioritize, design and facilitate the implementation of solutions to drive efficient, effective and high-quality delivery of new medicines, improving the health of people around the world. Dr. Gill is a member of the TransCelerate Board of Directors, and spearheads a culture of collaboration amongst TransCelerate’s 20+ Member Companies, and an aggressive agenda that seeks to advance innovation in R&D, identify and solve common R&D challenges and further improve patient safety, with the goal of delivering more high quality medicines to patients. Prior to his appointment as CEO of TransCelerate, he was the President of an international contract research organization. Dr. Gill earned his BSc in Applied Biology from the University of Hertfordshire and his PhD in Pathobiology from the Royal Free Hospital School of Medicine, University of London. He also holds a diploma in the Health Economics of Pharmaceuticals from the executive program of the Stockholm School of Economics. Dr. Gill has presented his research and spoken at numerous conferences, and has authored more than 30 scientific publications. He also is an elected fellow of the Royal Society of Medicine.